Latest Breaking News On - Masaryk memorial cancer institute - Page 1 : comparemela.com

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab) | Proteins and Peptides

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Czech republicUnited statesRichard sachsePeter grellMerck co incMerck sharp dohmeGustave roussy cancer centerMasaryk memorial cancer instituteSuperagonist technologyDrug developmentFirst patientSwitzerlandi julyChief medical officerManaging directorInpatient unitMerck sharp

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA (pembrolizumab)

AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck & Co., Inc., Rahway, NJ, USA), will supply KEYTRUDA for the study

United statesCzech republicKostenloser wertpapierhandelRichard sachseMichael tattoryPeter grellRichard kapsaMerck co incLifesci communicationsMerck sharp dohmeMasaryk memorial cancer instituteDrug development of gustave roussy cancer centerSuperagonist technologyChief medical officerManaging directorInpatient unit

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Investegate announcements from SOTIO Biotech, SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Czech republicUnited statesRichard sachseMichael tattoryPeter grellRichard kapsaMerck co incMerck sharp dohmeLifesci communicationsMasaryk memorial cancer instituteDrug development of gustave roussy cancer centerSuperagonist technologyFirst patientChief medical officerManaging directorInpatient unit

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Czech republicUnited statesRichard sachsePeter grellMerck co incMerck sharp dohmeMasaryk memorial cancer instituteDrug development of gustave roussy cancer centerSuperagonist technologyChief medical officerManaging directorInpatient unitDrug developmentGustave roussy cancer centerMerck sharp

SOTIO Biotech: SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer

CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)The trial will enroll up to 109 patients with gastric and pancreatic cancer PRAGUE

Czech republicUnited statesKostenloser wertpapierhandelRadka obermannovaJosep taberneroMichael tattoryRadek spisekRichard kapsaLifesci communicationsHebron university hospitalMasaryk memorial cancer instituteMedical oncology